September 28, 2016 / 12:37 PM / 2 years ago

BUZZ-U.S. STOCKS ON THE MOVE-Nike, Tempur Sealy, Anavex, BlackBerry

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter,; for the Morning News Call newsletter, U.S. stock index futures were little changed on Wednesday as investors awaited Federal Reserve Chair Janet Yellen's testimony before a Congressional Committee. Dow Jones industrial average futures were up 0.08 percent at 18,153, S&P 500 futures were up 0.06 percent at 2,154 and Nasdaq 100 futures were up 0.09 percent at 4,865.

** NIKE INC, Tuesday close $55.34, -2.69 pct premarket

At least six brokerages cut their price targets on the sportswear and footwear maker’s stock as future orders missed analysts’ estimates for the third time in a row.

** TEMPUR SEALY INTERNATIONAL INC, Tuesday close $74.45, -21.56 pct premarket

** SELECT COMFORT CORP, Tuesday close $25.12, -7.68 pct premarket

Tempur Sealy said it expected a 1-3 percent fall in full-year revenue, compared with a year earlier, and cut its adjusted EBITDA forecast.

** ORIGIN AGRITECH LTD, Tuesday close $2.33, +47.64 pct premarket

The agricultural biotechnology company said on Tuesday that it would sell its China-based commercial corn seed production and distribution unit for about $60 mln to Beijing Shihui Agricultural Development Co Ltd.

** SAREPTA THERAPEUTICS INC, Tuesday close $59.1, +4.03 pct premarket

RBC raised its price target on the drugmaker’s stock to $108 from $83.

** ANAVEX LIFE SCIENCES CORP, Tuesday close $3.14, +20.38 pct premarket

** BIOGEN INC , Tuesday close $314.53, +1.74 pct premarket

Anavex entered into an agreement with Biogen, under which Biogen will test Anavex’s lead experimental drug, Anavex 2-73.

** GALECTIN THERAPEUTICS INC, Tuesday close $2.47, -50.61 pct premarket

The drug developer said the mid-stage clinical trial evaluating the safety and tolerability of its lead drug, GR-MD-02, in 30 nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis did not meet primary and secondary goals.

** BLACKBERRY LTD, Tuesday close $7.88, +2.66 pct premarket

The company will outsource manufacturing of its once-core hardware, including its flagship smartphone, the Canadian company said as it reported another loss and sharp drop in revenue.

** AT&T INC, Tuesday close $41.46, -0.96 pct premarket

UBS cut the rating on the wireless carrier’s stock to “neutral”. (Compiled by Aishwarya Venugopal in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below